TherapeuticsMD (TXMD) PT Lowered to $5 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
TherapeuticsMD Announces First Quarter 2021 Financial Results
May 6, 2021 7:00 AM EDT- 1Q21 total net revenue increased to $19.9 million -
- 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 -
- ANNOVERA prescriptions continue to grow with increasing consumer support and acceptance -
- Further strengthened ANNOVERA® patent family through June 2039
- Significantly improved average net revenue per unit for IMVEXXY® to $61 and BIJUVA® to $69 -
-vitaCares divesture process continues in an effort to unlock shareholder value-
- Conference call scheduled... More
